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This review on childhood asthma focuses on acute
and chronic management in relation to the asthma
phenotypes reviewed in our previous article.1 It
includes when to refer to hospital services and updates
on new and emerging treatments.
Managing asthma requires not only an understand-
ing of specific treatments but also a commitment to
supporting the child and family as they learn to deal
with this long term illness. Key areas of management
include acute asthma management plans, day to day
“preventer” treatments, monitoring for side effects,
and an emphasis on trying to achieve a normal level
of functioning. For young children and those with
atypical features, repeated review also provides an
opportunity to revisit the diagnosis.
What is the acute management of asthma and episodic
viral wheeze?
An exacerbation of asthma can occur at any time and in
childhood ismost commonlyprecipitatedbyviral upper
respiratory tract infections. The British Thoracic
Society/Scottish Intercollegiate Guidelines Network
guideline recommends that all patients with asthma
should have a written, individualised asthma manage-
ment plan that includes clear and easy to follow instruc-
tions on acute management and guidance on daily
treatment and when to call emergency services (fig 1).2
The management of episodic viral wheeze is contro-
versial. Many doctors still favour an acute wheeze
management plan similar to that used in acute asthma,
with the use of regular bronchodilators and corticoster-
oids. Little evidence exists in the literature to support
this approach, however. A Cochrane review of short
acting β2 agonists found eight studies involving 229
patients and found no benefit in episodic viral
wheeze and persistent wheeze in children under the
age of 2 years.4 The benefit of anticholinergics in the
management of episodic viral wheeze is similarly
unclear. A Cochrane review of six studies involving
321 infants under the age of 2 years showed no impact
on symptoms or clinical course of the acute illness.5
The studies were heterogeneous, however, leaving the
possibility of a subgroup thatmaybenefit. Currently, the
indiscriminate use of anticholinergics and short acting β2
agonists in the management of acute episodic viral
wheeze is not recommended. Although these agents
are still used for young children with wheeze, the doctor
should ensure that a clear clinical benefit is achieved
before they are regularly prescribed.
A short course of systemic corticosteroids at the
onset of symptoms of episodic viral wheeze has been
shown to reduce the need for additional drugs in
infants admitted to hospital,6 7 and the use of high
dose (1.6-2.25 mg/day) inhaled corticosteroids may
also have some benefit if given at the onset of symp-
toms of upper respiratory tract infection in children
known to have episodic viral wheeze.8
What is the long term management of atopic asthma?
The British Thoracic Society/Scottish Intercollegiate
Guidelines Network guideline has clearly defined the
long term management of atopic asthma,2 with varia-
tions according to the age of the child (figures 2 and 3).
Treatment follows a stepwise approach until control is
achieved, and patients are thenmaintained on the low-
est level of treatment that still achieves control. The
latest update to the guidelines in 2005 recommended
changes in four key areas. (1) Inhaled corticosteroids
should be introduced in milder cases than previously
recommended. (2) Education should be offered to
families, and each child should receive an individual
asthma management plan. (3) Clinicians in primary
care should have specific training in asthma manage-
ment, as this improves diagnosis, prescribing, educa-
tion, monitoring, and continuity of care. (4) Patients
with asthma who are admitted to hospital should be
reviewed by clinicians with particular expertise in
asthma management, preferably within 30 days.
We will not repeat in this review all the advice given
in the guideline. However, a few areas are worth
specific comment.
Inhaled corticosteroids—friend or foe?
The introduction of inhaled corticosteroids has trans-
formed the management of chronic asthma.9
Searches and selection criteria
This review draws on the chapter on asthma and other
wheezing disorders in children in Clinical Evidence,
search date October 2006. We searched Medline in
January 2007 with the terms asthma, viral induced
wheeze, childhood, prevalence, symptoms, diagnosis,
management, corticosteroids, and adrenal
suppression.We also used the British Thoracic Society/
Scottish Intercollegiate Guidelines Network guideline
on the management of asthma
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Considerable benefit for all major clinical outcome
measures is seen with low and moderate doses
(beclametasone to 400 µg/day or fluticasone to
200 µg/day). Beyond this, however, the dose response
curve is relatively flat,10 and increases bring only
limited improvement.
Although side effects are unlikely at doses of 400 µg/
day of beclometasone equivalent,11 they have become
apparent at the higher doses. ACochrane review of the
effect of inhaled corticosteroids on height has
suggested that height velocity in the short term is
reduced with doses of over 400 µg/day beclometasone
(0.8 cm/year),12 13 but longer term studies have shown
that children do in fact attain a normal adult height.14 A
more worrying concern in recent years has been
reports of adrenal suppression in children taking
higher dose inhaled corticosteroid,15 16 several reports
with clinical evidence of acute adrenal crisis with
hypoglycaemia,11 17 and one reported death in 2001.18
These reports have prompted some asthma specialists
to recommend that all children on “off licence” doses
of inhaled corticosteroid (licensed doses for children
are up to 800 µg/day beclometasone or budesonide,
which is equivalent to 400 µg/day fluticasone) should
have a low dose short adrenocorticotrophic hormone
stimulation test.15 Caution is needed in interpreting the
results of this test, however, as the repeatability in
children with asthma has recently been questioned.19
Practically, if a child seems to need higher doses of
inhaled corticosteroid than those recommended by the
manufacturer, questions that need to be considered are:
 Is the diagnosis correct?
 Is the asthma genuinely severe?
 Are avoidable triggers present?
 Is concordance and delivery adequate?
 Are other treatments available that could be added
to reduce the dose of inhaled corticosteroid
needed?
This will ensure that all treatment options are
maximised and alternatives considered before the
dose of inhaled corticosteroid is increased to one that
may result in serious adverse effects.
Long acting β agonists in asthma
Onemethod of achieving better asthma control without
increasing the dose of inhaled corticosteroids is the
addition of long acting β2 agonists. These offer a longer
duration of bronchodilation in childrenwhenused inter-
mittently as a single dose,20 and in adolescents and adults
the addition of a long acting β2 agonist to regular inhaled
corticosteroids provides better control of symptoms
than does doubling the dose of inhaled
corticosteroids.21 The British Thoracic Society/Scottish
Intercollegiate Guidelines Network guideline advocates
a trial of the addition of short acting β2 agonists in
patients not controlled sufficiently on inhaled cortico-
steroid alone. However, in the paediatric population, no
evidence exists of a bronchodilator effect or protection
against exacerbations with the addition of short acting
β2 agonists to inhaledcorticosteroids.22Moreover, several
studies have shown an increased risk of exacerbation and
hospital admission in children on this combination.22
Evidence also exists of reduced protection against
Asthma exacerbation 
2-10 puffs salbutamol 100 µg up to
four hourly via large volume spacer*
Little or no
improvement
Responding to high
doses four hourly
Responding
well
Call ambulance
Give one puff
  salbutamol every
  30 seconds
  through large
  volume spacer
Start oral
  corticosteroids
Start oral
corticosteroids
for 3-5 days
Continue treatment
Look for signs
of deterioration
Fig 1 | Information to be incorporated into an individual asthma
management plan.
*Use of large volume spacer to deliver bronchodilator has
been shown to be as effective as delivery through nebuliser,3
but adequate doses of bronchodilator must be administered
Features that warrant referral to a specialist clinic
Feature Comment
Poor response to 800 µg/day beclometasone (or equivalent) Patient has reached step 4 of BTS/SIGN guideline and should be on other
asthma treatments; concordance and drug delivery need careful
assessment
Poor response to 400 µg/day beclometasone (or equivalent) and needs
add-on treatments that general practitioner is unfamiliar with
Young child (<5 years); uncertainty about drug delivery Needs careful assessment of inhaler techniques and expertise of
specialist asthma nurse
Young child (<1 year); often doubt about diagnosis
Features that point to another diagnosis
Recurrent admission to hospital Suggests dangerous pattern of asthma
Particularly severe acute asthma, such as needing intravenous treatments
or intensive care
These high risk patients should always be referred
BTS/SIGN=British Thoracic Society/Scottish Intercollegiate Guidelines Network.
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exercise induced asthma with regular short acting β2
agonists. Recent studies in adults have shown an
increase in the relative risk of death from asthma with
the use of salmeterol.
These findings have raised concern about the use of
short acting β2 agonists as regular preventive treatment
in the paediatric population. A subgroup of paediatric
asthma patients who benefit from the addition of short
acting β2 agonists to inhaled corticosteroids may well
exist, but until appropriate studies are done the safety
of these drugs remains unclear.23 A short term trial in
patients poorly controlled on short acting β2 agonists
and inhaled corticosteroids alone should therefore be
followed by regular review and careful assessment of
the response to treatment, so that treatments can be
stopped if no clear benefit is shown.
Can inhaled corticosteroids help to prevent asthma
developing?
The development of asthma often starts with recurrent
discrete wheezy episodes.24 Early intervention in the
form of either episodic or regular inhaled cortico-
steroids has been suggested to prevent these infants
developing asthma in later life. However, several
studies have shown no disease modifying effect in this
group of patients.24-26 The current recommendations
are that inhaled corticosteroids should be reserved
for children with persistent symptoms.
How can drug delivery be optimised, both at home and
school?
To achieve optimum inhaled drug delivery for children
with asthma, the correct device must be prescribed
alongside education on how to use it, as poor inhaler
technique can mean that more than 80% of the drug is
swallowed, thus reducing effectiveness.27 The National
Institute for Health and Clinical Excellence has
published guidance on recommended inhaler devices
for children aged under 5 and 5-15 years.2829
Receipt of asthma inhalers by children at school can
often be of concern to parents. School staff are not
required to administer asthma drugs to pupils except in
an emergency situation, but many staff are happy to
help. School staff should have education on managing
pupils with asthma readily available, along with instruc-
tion on the correct ways to administer inhaled drugs.
This can be done through the school health adviser.
All schools should have their own policy on asthma.
Asthma UK (www.asthma.org.uk) has published com-
prehensive guidelines for the management of pupils
with asthma and recommendations for policy develop-
ment to which head teachers should be directed.
Do effective treatments for long term management of
episodic viral wheeze exist?
No regular drugs are currently recommended for the
prevention of episodic viral wheeze. Unlike atopic
asthma, regular low dose inhaled corticosteroids offer
no benefit in the prevention of episodic viral wheeze.8
Recently, leukotriene receptor antagonists have shown
somepromise in thepreventionof episodicviralwheeze.
Onemulticentre double blind study showed that regular
treatment with montelukast reduced the rate of exacer-
bations by 32% and corticosteroid use by 30%,30 but
larger independent trials are needed to support this.
When is referral to tertiary services warranted?
The point of referral to a specialised clinic depends on
many variables, including the expertise of the primary
care team, the support they have from nursing staff,
their locality, and ease of access to a specialised service.
Most general paediatricians will have good knowledge
and expertise in assessing and managing childhood
asthma and can provide a useful second opinion.How-
ever, not all have access to specialist asthma nurses or
investigations thatmight help to secure the diagnosis or
Refer to respiratory paediatrician
In children 2-5 years consider trial of leukotriene receptor antagonist
In children <2 years consider proceeding to step 4
Step 4
Step 2
Step 1
Step 3
Add in inhaled steroid 200-400 µg/day* or leukotriene
receptor antagonist if steroids cannot be used
Inhaled short acting β2 agonist
Fig 3 | Summary of British Thoracic Society/Scottish Intercollegiate Guidelines Network
guideline on management of asthma for children aged under 5 years.
*Or equivalent dose
Add in oral steroids and refer to respiratory paediatrician Step 5
Increase inhaled steroids to 800 µg/day*
- Add in LABA
- If good response continue LABA
- If inadequate response continue LABA and increase inhaled steroids to 400 µg/day*
- If no response stop LABA, increase inhaled steroids to 400 µg/day, consider trial of other
    therapies such as montelukast, theophylline
Step 4
Step 2
Step 1
Step 3
Add in inhaled steroid 200-400 µg/day*
Inhaled short acting β2 agonist
Fig 2 | Summary of British Thoracic Society/Scottish Intercollegiate Guidelines Network
guideline on management of asthma for children aged 5-12 years. LABA=long acting β2
agonist.
*Or equivalent dose
TIPS FORGENERAL PRACTITIONERS
 Establishing the asthma phenotype will help to guide
long term management
 Consider the possibility of an alternative diagnosis in
a child with difficult to control asthma
 Information about asthma treatment at school is
available from theAsthmaUK school policy guidelines
(2006)
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explore differential diagnoses. The British Thoracic
Society/Scottish Intercollegiate Guidelines Network
guideline recommends referral to a paediatrician with
specialised expertise in childhood asthmawhen a child
reaches step 4 (patients needing an increase in inhaled
beclometasone up to 800 µg/day or equivalent).2
However, if the general practitioner is unfamiliar
with treatments that are added on to inhaled
corticosteroids an earlier referral is sensible; indeed
most asthma specialist services will wish to receive
referrals if 400 µg/day of beclometasone or equivalent
is not achieving control. The table shows features that
might warrant referral.
What are the therapeutic options in severe asthma?
Occasionally, children do not respond well to conven-
tional treatments and continue to have symptoms or
even have severe, acute, or life threatening episodes of
asthma.These children aremanagedwith long termoral
prednisolone and need frequent visits to the specialised
asthma clinic, where symptoms and side effects can be
monitored.Themost commoncause forapoor response
to oral corticosteroids is non-compliance.31 If symptoms
persist despite regular steroid treatment, monthly
subcutaneous injections of steroid can be given to ensure
compliance. For those who continue to have poor
control, additional immunosuppression, such as
ciclosporin or methotrexate, may be tried. Although
little evidence exists for benefit in children, this option
is used in those who have severe side effects from oral
corticosteroids or continue to have severe asthma
despite exhausting all alternatives.
Alternative treatments include continuous subcuta-
neous terbutaline, which has been used with success in
the past and can be well tolerated.32 More recently, the
anti-IgE monoclonal antibody omalizumab has been
used in children with asthma as an alternative to
methotrexate. It binds to the IgE epitope that binds the
IgE receptor, thus preventing IgE mediated mast cell
degranulation. Several trials have shown clinical benefit
from omalizumab in the form of significantly fewer
exacerbations per patient and a significantly lower
percentage of patients having exacerbations.33 The two
weekly or four weekly subcutaneous injections seem to
be well tolerated, and some specific benefit seems to be
achieved, withmeasurable reductions in the dose of oral
prednisolone needed.
Some specialists advocate detailed invasive investiga-
tions in these difficult to treat patients, including
measurement of airway eosinophils and neutrophils in
broncho-alveolar lavages. They hypothesise that
different mechanisms are responsible in individual
cases and that targeting treatment to recognised sub-
groups—for example, ciclosporin for persistent eosino-
philic inflammation or azithromycin for persistent
neutrophilic inflammation31—is a more effective
strategy.Much still remains to be learnt, however, about
specific treatments in this difficult group of patients.
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My “memorable patient” story
When it comes to medical interviews, there are a few
classic questions, including “Tell me about a memorable
patient.” I used to hate this question. As a senior house
officer, I took “memorable” to mean the complex, clever
medical diagnosis or the difficult case that required clever
handling. Most people I knew, myself included, would
make up impressive sounding cases tailored to fit the
interview. Occasionally, I would use a real patient, as long
as there was something about their case that demonstrated
my skills or my ability to improve myself. As I was
generally successful at interviews, I assumed this was a
good approach.
One evening on call, I was idly chatting with the
consultant. He mentioned that “Tell me about a
memorable patient” was his favourite question.
He felt that the type of patient the candidate deemed
memorable was far more important than the details of the
case, and that this choice of patient told him more about
the candidate than any other question. I paid little
attention at the time, but, two years later, I still remember
this remark.
As I’ve progressed through my training, my attitudes
and opinions have changed. Memorable no longer means
challenging or complex. Of course, I’ve not been asked
the question since, but Iwish someonewould. If you asked
me today, I would not tell you about the clever diagnoses I
have made or the newborns I have successfully
resuscitated; I would tell you about just one child—my
favourite patient. I’d tell you about this boy who was
happy, well adjusted, and polite despite debilitating
chronic disease. I’d tell you how he never minded any
examination or test and how he had the wonderful gift of
making everyone around him feel happy and relaxed,
myself included.
With somany ofmy colleagues anxiously preparing for
interviews for specialist training posts, I am constantly
being asked for advice.While I try to help them formulate
answers, I remembermy conversation with the consultant
and my memorable patient. I tell my colleagues that
interviews are not just about you the doctor; they’re also
about you the person. Tell the interviewers about the
silliest, funniest, nastiest, or nicest children or parents you
have ever met: this reflection on your personality is just as
valid as, and probably more interesting than, a medical
diagnosis. And incidentally, although I remember the
child’s name, face, and personality perfectly, I can’t
remember his diagnosis.
Deborah Bird specialist registrar in paediatrics,
Darent Valley Hospital, Dartford
deborahbird@doctors.org.uk
We welcome articles up to 600 words on topics such
as A memorable patient, A paper that changed my practice,
My most unfortunate mistake, or any other piece
conveying instruction, pathos or humour. Please
submit the article on http://submit.bmj.com
Permission is needed from the patient or a relative if
an identifiable patient is referred to. We also welcome
contributions for “Endpieces,” consisting of quotations
of up to 80 words (but most are considerably shorter)
from any source, ancient or modern, which have
appealed to the reader.
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